Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.
PMID: 21784687
2011
International journal of infectious diseases
Abstract: RESULTS: Seven types of ADAPVEM were detected in the total CHB patients: rtM204V/sI195M, rtM204I/sW196S, rtM204I/sW196L, rtV173L/sE164D, rtA181T/sW172*, rtA181T/
[Variants and quasispecies of reverse transcriptase region in polymerase gene of hepatitis B virus during lamivudine treatment].
PMID: 21789847
2011
Zhonghua shi yan he lin chuang bing du xue za zhi
Abstract: The rtL180M variant was found in association with the rtM204I/V variant, HBV variants and wild-type in YMDD motif all existed together in these two groups.
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.
Abstract: An exception is rtM204I, which can derive from a transition or a transversion.
The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Abstract: rtA194T reduced replication by <40%, whereas rtL180M+rtM204V, Abstract: METHODS: A plasmid containing a wild-type 1.3 genome length genotype D HBV laboratory strain was used as a parent for PC, BCP, rtA194T+-rtL180M+rtM204V, rtL180M+rtM204V and rtM204I mutants.
The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
Abstract: HBV breakthrough occurred in one recipient at the month 12 post-OLT, with detectable serum HBV-DNA (740 copies/mL) and tyrosine-methionine-aspartate-aspartate motif mutation (rtM204I and rtM204V).
Evolution of hepatitis B virus during long-term therapy in patients with chronic hepatitis B.
Abstract: During ADV and LAM treatment, one patient developed ADV plus LAM resistance mutations (rtI163V+rtL180M+rtA181V+rtN236T), in this case, HBV strains harbouring polymerase mutations did not develop LAM associated rtM204V/I primary mutation.
Abstract: RESULTS: Three patients developed LAM resistance mutations (2 presented rtM204I and one rtL180M+rtM204V/I) and one patient showed
Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B.
Abstract: HBV reverse-transcriptase (RT) region was sequenced and analyzed for 20 mutations, confirmed by in vitro studies as associated with resistance to nucleos(t)ide HBV-RT inhibitors (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C/G/I-
Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
Abstract: Virological factors including HBV-DNA level, genotype, precore G1896A, BCP A1762T/G1764A, rtM204I/V, rtA181T and pre-S internal deletion mutations as well as clinical variables including subsequent use of rescue drugs were submitted for outcome analysis.
Method: The methods to detect HBV basal core promoter (BCP) A1762T/G1764A mutations, precore stop codon
HBV mutation literature information.
PMID: 
2011
International journal of infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT